CorMedix Inc. (CRMD)
About CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2025
- $311.7M
- Net income
- $163.1M
- Total assets
- $826.1M
- Market cap
- $617.4M
- Gross margin
- 88.5%
- Operating margin
- 48.2%
- Net margin
- 52.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $311.7M
- Cost of revenue
- $22.1M
- Gross profit
- $275.7M
- Operating expenses
- $125.6M
- Operating income
- $150.1M
- Income tax
- -$13.0M
- Net income
- $163.1M
- EPS (basic)
- $2.25
- EPS (diluted)
- $2.04
Balance sheet
- Total assets
- $826.1M
- Current assets
- $367.1M
- Total liabilities
- $420.8M
- Current liabilities
- $174.3M
- Shareholders’ equity
- $405.3M
Cash flow
- Operating cash flow
- $175.0M
- Investing cash flow
- -$308.4M
- Financing cash flow
- $238.5M
- Net cash flow
- $105.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $617.4M
- P/E ratio
- 4.1
- EPS (diluted)
- $2.04
- Shares outstanding
- 74.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 13, 2010
CorMedix Inc. (CRMD) Stock Price
- Profitable — net income of $163.1M in FY2025.
- Revenue grew 163153% from FY2021 to FY2025.
- Gross margin of 88.5%, net margin 52.3%.
- Trading 44% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 4.1.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review CorMedix Inc..
Write a review
News about CorMedix Inc.
News & sentiment via Polygon.io
CorMedix Inc.: frequently asked questions
Is CorMedix Inc. an American company?
CorMedix Inc. is a US-based company headquartered in Parsippany, New Jersey, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is CorMedix Inc. headquartered?
CorMedix Inc. is headquartered in Parsippany, New Jersey, United States.
Is CorMedix Inc. publicly traded?
Yes — CorMedix Inc. is a publicly traded company. Its stock trades under the ticker symbol CRMD on the NASDAQ.
What does CorMedix Inc. do?
CorMedix Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
